News

March 20, 2020March 20, 2020

One-Fifth of JIA Patients Switch Out 1st Biological Therapy, UK Study Reports

News

About one-fifth of patients with juvenile idiopathic arthritis (JIA) under age 16 are switched to second biological therapies after first-line treatments fail or cause adverse effects, a large real-world study ... Read more

March 17, 2020March 17, 2020

JIA Rheumatologist Wait Times Within Benchmarks, Canadian Study Finds

News

Children with juvenile idiopathic arthritis (JIA) generally saw rheumatologists within the recommended wait times, a Canadian single-center study found. Older patients waited longer, highlighting the need for better monitoring ... Read more

March 13, 2020March 13, 2020

Study: Adding RoActemra to Methotrexate Not Generally Effective in Lessening Uveitis in JIA Patients

News

Adding RoActemra (tocilizumab) to methotrexate failed to show effectiveness in children and adolescents with treatment-resistant uveitis — inflammation of the eye — associated with juvenile idiopathic arthritis (JIA), a Phase ... Read more

March 10, 2020March 10, 2020

Stopping Ilaris Post-remission Is Feasible in Systemic JIA Children, Study Finds

News

Treatment with Ilaris (canakinumab) can be discontinued without relapse in some children with systemic juvenile arthritis (sJIA), according to a recent small study. Sustained remission specifically appears to be ... Read more

March 6, 2020March 6, 2020

Parents Unaware of Current JIA Research, Study From Canada Reports

News

Parents of children with juvenile idiopathic arthritis (JIA) surveyed for a study in Canada were generally unaware of current research findings, though they said information about the latest studies ... Read more

March 5, 2020March 5, 2020

Video: BioNews’ Social Media Campaign Highlights #WhatMakesMeRare

News

In recognition of Rare Disease Day Feb. 29, BioNews Services launched a social media campaign last month asking patients to describe what makes them rare. Running Feb. 7–29, the ... Read more

March 3, 2020March 3, 2020

Early JIA Combo Therapy with Biologics Tops Standard Treatment, Study Finds

News

Early intervention with biological therapies to treat young patients with juvenile idiopathic arthritis (JIA) is more effective in reducing disease activity and improving quality of life than using only ... Read more

February 21, 2020February 21, 2020

S100 Proteins are Diagnostic and Disease Activity Markers in Systemic JIA, Study Suggests

News

Testing for S100A8/9 and S100A12 proteins may aid in the diagnosis of systemic juvenile idiopathic arthritis (sJIA) and serve as a marker of disease activity, a study suggests. The ... Read more

February 18, 2020February 18, 2020

Investigators Create New Tool to Evaluate the Impact of JIA on Caregivers

News

Investigators have created a new questionnaire to assess the psychosocial and economic impact of juvenile idiopathic arthritis (JIA) on caregivers of children with the disease. The new tool was described in ... Read more

February 14, 2020February 14, 2020

Actemra Can Mask Macrophage Activation Syndrome in Systemic JIA, Study Reports

News

Treating systemic juvenile idiopathic arthritis (sJIA) with Actemra (tocilizumab) can modify the clinical and laboratory features of macrophage activation syndrome (MAS) — a severe, potentially life-threatening complication of rheumatic diseases ... Read more

Pin It on Pinterest